Brief Title
Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
Official Title
Superiority of Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
Brief Summary
The hypothesis of the study is to address the efficacy and toxicity profile of aforementioned
four modalities for rT1-2 NPC.
Characters of the patients:
- list item one: 168 patients, median age 48 years (range 16-75 years） proven rT1-2 NPC
were diagnosed
- list item two: Treated with four different irradiation modalities(3D-CRT,IMRT, BT , BT
Combined 3D-CRT or IMRT).
- list item three: Median time to recurrence was 30 months (range 1-180months). The median
follow-up time was 28 months (range, 4-135 months).
Detailed Description
Objectives:
Recurrent T1-2 Nasopharyngeal Carcinoma (rT1-2) may be salvaged by 3D - CRT（3D-Conformal
Radiotherapy）, IMRT（ Intensity Modulated Radiotherapy）, Brachytherapy (BT), BT combined 3D -
CRT or IMRT . The aim of this study is to address the efficacy and toxicity profile of
aforementioned four modalities for rT1-2 NPC.
Methods and Materials:
168 patients, median age 48 years (range 16-75 years） proven rT1-2 NPC were diagnosed and
treated with four different irradiation modalities(3D-CRT,IMRT, BT , BT Combined 3D-CRT or
IMRT) . Median time to recurrence was 30 months (range 1-180months). The median follow-up
time was 28 months (range, 4-135 months).
Study Type
Interventional
Primary Outcome
all cause mortality
Condition
Nasopharyngeal Cancer Recurrent
Intervention
3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
Study Arms / Comparison Groups
recurrent T1-2 NPC,no treatment
Description: 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Radiation
Estimated Enrollment
168
Start Date
January 1996
Completion Date
March 2011
Primary Completion Date
June 2009
Eligibility Criteria
Inclusion Criteria:
- recurrent T1-2 nasopharyngeal carcinoma patients
Exclusion Criteria:
- non recurrent T1-2 nasopharyngeal carcinoma patients
Gender
All
Ages
16 Years - 75 Years
Accepts Healthy Volunteers
No
Contacts
Jianji Pan, MD, ,
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT02113423
Organization ID
FJCH009911
Responsible Party
Sponsor
Study Sponsor
Fujian Cancer Hospital
Study Sponsor
Jianji Pan, MD, Study Director, Department of Radiation Oncology, Cancer Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China
Verification Date
April 2014